CooperCompanies Appoints Paul Keel to its Board of Directors
CooperCompanies has appointed Paul Keel as an independent director effective July 1, 2026. He will also join the Audit Committee. Keel is currently the CEO of Envista Holdings and has previously led several companies, including Smiths Group and various roles at 3M. His extensive experience in the medical device sector is expected to contribute to CooperCompanies’ strategy of creating long-term value.
SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) — CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board.